Read by QxMD icon Read


Caitlyn Solem, Reema Mody, Jennifer Stephens, Cynthia Macahilig, Xin Gao
OBJECTIVE To describe physicians' knowledge, patients' adherence, and perceptions of both regarding mealtime-related dosing directions for proton-pump inhibitors (PPIs). DESIGN Chart review and survey of patients and physicians. SETTING United States, with data collected between January and July 2011. PARTICIPANTS Patients being treated for gastroesophageal reflux disease (GERD) with PPIs and their prescribing physicians. MAIN OUTCOME MEASURES Patient- and physician-reported perception of PPI mealtime-related directions as important/inconvenient (seven-point Likert scale; 7 = very important/very inconvenient); physician-reported knowledge of PPI mealtime-related dosing directions based on whether the agent is labeled to be taken 30-60 minutes before eating (DIR-esomeprazole magnesium [Nexium-AstraZeneca], lansoprazole, and omeprazole) or labeled to be taken regardless of meals (NoDIR-dexlansoprazole [Dexilant-Takeda], rabeprazole, and pantoprazole); and patient-reported PPI mealtime-related directions received and adherence to directions...
March 2014: Journal of the American Pharmacists Association: JAPhA
Brian W Behm, David A Peura
Dexlansoprazole modified release (MR; Dexilant™), the R-enantiomer of lansoprazole, was approved in the USA in 2009 for the management of erosive esophagitis and nonerosive reflux disease. Dexlansoprazole MR has a unique dual delayed-release delivery system that was designed to address unmet needs that may accompany the use of single-release proton pump inhibitors (PPIs), specifically, their short plasma half-life and requirement for meal-associated dosing. The delivery technology of dexlansoprazole MR is designed to release the drug in two separate pH-dependent phases, the first in the proximal duodenum and the second in the more distal small intestine...
August 2011: Expert Review of Gastroenterology & Hepatology
M Marigo, S D Ferrara, L Tedeschi
The Authors present a gas-chromatographic method which allows for the rapid identification and assay of barbiturates and antiepileptics in body fluids. The Kupferberger procedure for extraction is used. The identification is obtained on two different columns: 10% Dexil 300 GC on Chromosorb W-HP and 3% OV 17 on Chromosorb G AW-DMCS (80-100 mesh). A considerable and interesting reduction of the barbiturates adsorption in the columns is obtained by preliminary conditioning with tetraethylorthosilicate. In this way, phenobarbital and cyclobarbital may also be assayed up to 1 microgram/ml in blood...
June 18, 1977: Archives of Toxicology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"